Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2566)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE PUBLIC FLOAT

Reference is made to the announcement of Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (the "**Company**") dated March 5, 2026 (the "**Announcement**") in relation to its public float. Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

SUPPLEMENTAL INFORMATION ON PROPOSAL TO RESTORE PUBLIC FLOAT

In addition to the information disclosed in the Announcement, the Board would like to provide additional information in relation to the progress of the Company's H Share full circulation, which is to convert 136,302,015 unlisted Shares held by 12 Shareholders into H Shares (the "**H Share Full Circulation**"). Upon completion of the H Share Full Circulation and assuming there is no other change in the shareholding of the Company's core connected persons, the public float is expected to increase to approximately 31.13%, thereby restoring compliance with the Minimum Prescribed Percentage.

The H Share Full Circulation was approved at the Company's extraordinary general meeting held on December 22, 2025, and the Company submitted its filing application (the "**Filing Application**") for the H Share Full Circulation to the China Securities Regulatory Commission (the "**CSRC**") on December 23, 2025. The Company expects to receive the filing notice from the CSRC (the "**Filing Notice**") by the end of April 2026. Following the receipt of the Filing Notice, the Company plans to complete all necessary procedures for the H Share Full Circulation within the second quarter of 2026, subject to the timing of regulatory reviews and approvals. The Company will respond in a timely manner to any questions or requests raised by the CSRC regarding the Filing Application and make further announcement(s) on the progress of the H-Share Full Circulation as and when appropriate.

The Company will continue to monitor the issue of insufficient public float and will make monthly announcements in accordance with the Listing Rules to keep Shareholders and the market informed of the progress made in restoring the public float.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
FU Hang
Executive Director, Chairman of the Board and General Manager

Hangzhou, the PRC, March 25, 2026

As of the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; and (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀) and Dr. Zhou Demin (周德敏) as independent non-executive directors.